<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002977</url>
  </required_header>
  <id_info>
    <org_study_id>1181.00</org_study_id>
    <secondary_id>1181.00</secondary_id>
    <secondary_id>NCI-G97-1229</secondary_id>
    <secondary_id>CDR0000065499</secondary_id>
    <nct_id>NCT00002977</nct_id>
  </id_info>
  <brief_title>Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission</brief_title>
  <official_title>A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation&#xD;
      may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of melphalan and thiotepa followed by&#xD;
      peripheral stem cell transplantation in treating patients with stage III or stage IV&#xD;
      epithelial ovarian cancer in complete remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Assess the toxic effects of combined high dose melphalan and thiotepa&#xD;
      chemotherapy followed by stem cell rescue in patients with stage III or IV ovarian epithelial&#xD;
      cancer in complete remission. II. Determine the maximum tolerated dose of thiotepa that can&#xD;
      be given with melphalan in these patients. III. Evaluate the interpatient blood level&#xD;
      variability and pharmacokinetics of melphalan given intravenously.&#xD;
&#xD;
      OUTLINE: This is a dose escalation study of thiotepa. Patients receive cytoreduction and&#xD;
      mobilization of peripheral blood stem cells (PBSC) with filgrastim (G-CSF) and&#xD;
      cyclophosphamide/paclitaxel, cyclophosphamide/etoposide or&#xD;
      cyclophosphamide/etoposide/cisplatin within 30-90 days of last dose of standard therapy. PBSC&#xD;
      are then collected. Patients then receive melphalan IV over 30 minutes on days -6 and -5 and&#xD;
      thiotepa IV over 2 hours on days -4 and -3. PBSC are reinfused on day 0. G-CSF is&#xD;
      administered on days 0-21. Cohorts of 5-15 patients each receive escalating doses of thiotepa&#xD;
      until the maximum tolerated dose (MTD) is reached. The MTD is determined as the dose at which&#xD;
      2-5 of 4-15 patients experience dose limiting toxicity. Patients are followed at 100 days,&#xD;
      then at 6, 12, and 24 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30-45 patients will be accrued for this study over 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1997</start_date>
  <primary_completion_date type="Actual">November 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed stage III/IV ovarian epithelial cancer in&#xD;
        first or second clinical complete remission after receiving a minimum of 4-10 courses of&#xD;
        chemotherapy consisting of paclitaxel and either cisplatin or carboplatin Ovarian&#xD;
        epithelial cancer of following histologic types: Serous adenocarcinoma Mucinous&#xD;
        adenocarcinoma Clear cell adenocarcinoma Transitional cell Adenocarcinoma N.O.S.&#xD;
        Endometrioid adenocarcinoma Undifferentiated carcinoma Mixed epithelial carcinoma Malignant&#xD;
        Brenner's Tumor Remission stability maintained for at least 4 weeks Protocol therapy must&#xD;
        begin 30-90 days after last dose of standard therapy No active pleural or pericardial&#xD;
        effusion No prior/concurrent brain metastasis or carcinoid meningitis&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 to 60 Performance status: Karnofsky 70-100% Life&#xD;
        expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 1.5&#xD;
        times the upper limit of normal (ULN) SGOT or SGPT less than 2.0 times ULN Albumin greater&#xD;
        than 2.0 g/dL Renal: Creatinine clearance greater than 60 mL/min Cardiovascular: Ejection&#xD;
        fraction greater than 45% by MUGA Pulmonary: If history of smoking or abnormal lung&#xD;
        function, Diffusion capacity greater than 50% (corrected) A-a gradient less than 20 Other:&#xD;
        No history of hemorrhagic cystitis No second malignancy within the last 5 years except&#xD;
        basal cell skin cancer HIV negative No chronic active hepatitis B No hepatitis C No history&#xD;
        of Aspergillus infection&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior stem cell transplant Chemotherapy:&#xD;
        Prior chemotherapy consisting of paclitaxel and either cisplatin or carboplatin Endocrine&#xD;
        therapy: Not specified Radiotherapy: No prior radiation therapy for malignancy (excluding&#xD;
        chest wall radiation therapy for breast cancer) Surgery: Not specified&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leona A. Holmberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fred Hutchinson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 28, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2004</study_first_posted>
  <last_update_submitted>September 13, 2010</last_update_submitted>
  <last_update_submitted_qc>September 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2010</last_update_posted>
  <keyword>stage III ovarian epithelial cancer</keyword>
  <keyword>stage IV ovarian epithelial cancer</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>ovarian mixed epithelial carcinoma</keyword>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>Brenner tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

